A retrospective study from Australia now gives prescribers and addiction treatment providers rare real-world evidence on what can reduce that harm.

After high-profile media coverage, tighter dispensing rules, and boxed warnings, pregabalin prescriptions fell 25% below projected trends and overdoses fell 47%, researchers reported in The BMJ.

Three Interventions That Preceded the Decline

Rose Cairns, PhD, of the University of Sydney, and co-authors examined dispensing claims and poison center overdose data from 2016 to 2024, tracking three events: widespread media reporting about pregabalin’s harms in December 2018, tighter prescribing restrictions introduced after April 2020, and boxed warnings added in February 2021.

Dispensing dropped significantly at three time points: December 2018, following the press coverage; May 2020, after the tighter restrictions; and December 2021, after the boxed warnings took effect.

The shift corresponded to ongoing monthly reductions of 0.7% in prescriptions and 1.6% in poison center overdose calls, reversing a steep upward trajectory that had persisted since 2013. Use and overdoses had peaked in 2018.

Pregabalin Prescribing in the United States

Gabapentinoids, the drug class that includes pregabalin and gabapentin, were originally developed as antiseizure medications.

Approved uses later grew to include neuropathic pain, postherpetic neuralgia, and fibromyalgia, yet most consumption comes from off-label prescribing, according to Cairns and her co-authors.

In the United States, pregabalin is scheduled under the Controlled Substances Act. Gabapentin carries no federal scheduling, though eight states have enacted legislation classifying it as a schedule V controlled substance.

In 2019, the FDA warned that respiratory depression or death may occur in patients taking pregabalin or gabapentin with opioid pain medicines or other drugs that depress the central nervous system. Co-prescribing of gabapentinoids and opioids persists despite that warning.

In the United Kingdom, one-third of substance use deaths involve a gabapentinoid, predominantly pregabalin, and deaths involving gabapentinoids more than doubled from 2018 to 2022, the researchers noted.

The findings are “really positive, but we think use of pregabalin is still far too high,” Cairns said. “There’s a lot of off-label use for conditions with minimal evidence to back that up. And while high-risk use has decreased, we really need to continue to minimize co-use with opioids, which has been shown to increase the risk of death.”

What the Study Measured and Its Limits

The researchers randomly sampled 10% of Australians with drug subsidies and 50% of calls placed to the country’s largest poison control center.

During the study period, 227,864 people were dispensed 3,441,851 pregabalin prescriptions, and poison centers logged 4,871 pregabalin overdose calls.

The analysis covered subsidized prescriptions only, poison center data may be subject to reporting bias, and the researchers could not determine patients’ access to pain treatments.

David Juurlink, MD, PhD, of the Sunnybrook Health Sciences Centre in Toronto, urged caution in an accompanying editorial. “The ecological design cannot establish causation, and poison center calls are an imperfect measure of poisoning incidence, influenced by reporting practices and patterns of healthcare use,” he wrote.

What This Means for Treatment Seekers

People who take pregabalin or gabapentin with opioid pain medication face an increased risk of respiratory depression and death, according to the FDA.

Anyone concerned about their own use of these medications, or a loved one’s, can ask a prescriber about safer pain treatment alternatives and whether a taper is appropriate.

Misuse of prescription medications is treatable, and addiction treatment programs routinely address prescription drug dependence alongside opioid use.

Exploring Addiction Treatment Options

People comparing rehab centers can look for programs that treat prescription drug misuse and offer medication management during detox and residential care.

Verifying facility credentials and asking how a program handles polysubstance use can help narrow the options. Rehab.com’s directory includes verified treatment centers nationwide. Get in contact with a treatment advisor by calling 800-985-8516 ( Question iconSponsored Helpline ) .